Clinigen has delivered a trading update that looks at least in line with expectations for the year ended Jun-15 and indicates the integration of IDIS is proceeding to plan. Revenues are expected to be at least £183.6m (+45% YoY) driven by organic growth and a 2m contribution from IDIS. EBITDA growth of 20% to at least £32.2m was split 50:50 between organic and acquisitive. No change to consensus expected.
